Minerva Neurosciences (NERV) KOL event summary

Introduction and agenda

• Event focused on the unmet need for treating negative symptoms in schizophrenia and the development of roluperidone, with updates on clinical trial design, regulatory alignment, and KOL presentations, followed by a Q&A session.

KOL background and credentials

• Presenters included Professors Gregory Strauss and Brian Kirkpatrick, recognized experts who have chaired national consensus conferences on negative symptoms, and Dr. Remy Luthringer.

Market insights and analysis

• Schizophrenia affects 83 million globally, with a $34 billion annual US burden; negative symptoms are underdiagnosed, undertreated, and the strongest predictor of poor functioning, with no FDA-approved therapies.

• Avolition is identified as the central hub of negative symptoms, driving poor functional outcomes.